Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access
Find out how Blood Cancer United’s luveltamab access move could reshape rare pediatric AML drug rescue models.
Pharma & Biotech
Pharma & Biotech
Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment
OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.
Pharma & Biotech
Can REYOBIQ improve Plus Therapeutics’ path in pediatric high-grade glioma and ependymoma?
Plus Therapeutics won orphan drug designation for REYOBIQ in pediatric malignant gliomas. Read what it changes for CNS cancer development.
Pharma & Biotech
Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors
Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.
Pharma & Biotech
What Theriva Biologics’ APAO 2026 presentation signals for intravitreal oncology treatments
Theriva’s APAO 2026 VCN-01 data reveals how viral synergy and local delivery could redefine pediatric eye cancer care.
Pharma & Biotech
Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA
FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.
Pharma & Biotech
What Orphalan’s Orphelia Pharma acquisition reveals about the next phase of rare pediatric drug consolidation
Orphalan, the international pharmaceutical company known for developing orphan drugs, has announced the acquisition of Orphelia Pharma, a specialist in rare and severe pediatric diseases. The deal enhances Orphalan’s position in the European rare disease market, particularly within pediatric neurology and oncology, and signals a strategic pivot toward deeper vertical integration in pediatric formulations and